Louvain-La-Neuve, Belgium, November 19, 2021 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed a contract for the installation of a Proteus®ONE[1] proton therapy turnkey solution with the Oncology Reference Center (C.R.O.) in Aviano, Italy. IBA was selected as the preferred supplier following a comprehensive vendor selection process. IBA expects to receive a down payment in the coming weeks.

This Proteus®ONE, the 31st to be sold by IBA globally, will be integrated into the current radiotherapy department at C.R.O. and is expected to start treating patients by the end of 2024.

Olivier Legrain, Chief Executive Officer of IBA, commented: “We are pleased to sign this new contract with C.R.O. to bring much needed proton therapy to cancer patients in Italy. Securing a new proton therapy contract in Europe demonstrates IBA’s superior market offering as well as the global demand for this technology as we continue to see building momentum for this treatment modality. We look forward to collaborating with C.R.O. and welcome them to our Campus community, where they can interact with other clinicians through the world’s first online platform dedicated to proton therapy: www.campus-iba.com.”